Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-19 9:52 pm Sale | 2023-07-18 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 25,120,991 15.700% | -1,500,000 (-5.63%) | Filing History |
| 2023-02-14 4:18 pm Purchase | 2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 9,823,908 6.420% | 820,697 (+9.12%) | Filing History |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | BridgeBio Pharma, Inc. BBIO | The Vanguard Group | 10,591,455 7.090% | 1,259,772 (+13.50%) | Filing History |
| 2023-02-08 10:30 am Purchase | 2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | STATE STREET CORP STT | 8,844,943 5.920% | 8,844,943 (New Position) | Filing History |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 9,834,401 6.600% | 558,811 (+6.02%) | Filing History |
| 2022-02-14 9:01 pm Purchase | 2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Perceptive Advisors LLC | 7,128,755 4.800% | 422,487 (+6.30%) | Filing History |
| 2022-02-14 4:50 pm Purchase | 2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 9,003,211 6.050% | 672,614 (+8.07%) | Filing History |
| 2022-02-09 3:33 pm Purchase | 2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | The Vanguard Group | 9,331,683 6.340% | 2,890,371 (+44.87%) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 9,275,590 6.300% | 2,758,046 (+42.32%) | Filing History |
| 2021-02-17 5:28 pm Sale | 2020-02-11 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 31,060,971 20.900% | -3,450,000 (-10.00%) | Filing History |
| 2021-02-16 5:02 pm Sale | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 8,330,597 6.740% | -288,186 (-3.34%) | Filing History |
| 2021-02-16 3:36 pm Unchanged | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Perceptive Advisors LLC | 6,706,268 5.500% | 0 (Unchanged) | Filing History |
| 2021-02-12 7:33 pm Sale | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | AMERICAN INTERNATIONAL GROUP INC. AIG | 3,381,412 2.800% | -3,383,180 (-50.01%) | Filing History |
| 2021-02-10 10:39 am Purchase | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | The Vanguard Group | 6,441,312 5.250% | 6,441,312 (New Position) | Filing History |
| 2021-02-05 07:51 am Purchase | 2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 6,517,544 5.300% | 6,517,544 (New Position) | Filing History |
| 2021-01-26 4:23 pm Sale | 2021-01-26 | 13D | BridgeBio Pharma, Inc. BBIO | Eidos Therapeutics Inc. EIDX | 0 0.000% | -44,651,896 (Position Closed) | Filing History |
| 2021-01-26 09:00 am Sale | 2021-01-26 | 13D | EIDOS THERAPEUTICS INC EIDX | BridgeBio Pharma Inc. BBIO | 1,000 100.000% | -24,574,501 (-100.00%) | Filing History |